19 Jul Akadeum Life Sciences
Brandon McNaughton, Ph.D., CEO & Co-founder
Oct. 7 | 5:15pm | FLW Ballroom G
Ann Arbor, MI
(Private)
Akadeum Life Sciences’ next generation cell isolation platform solves long-standing problems in cell therapy and research: time, cost, cell health, scalability. The first new GMP cell separation modality in 40 years, Akadeum’s buoyant microbubble technology represents one of the first meaningful innovations in a critical early step of the cell therapy manufacturing process. Kits are readily incorporated into workflows without the need to purchase equipment or overhaul processes, delivering consistently high performance while enabling up to a 42% reduction in workflow footprint, reducing GMP suite time by 80% and training requirements down to one hour, all via a simple closed system in-bag cell separation done at any scale, with any starting material. Microbubbles are compatible with both centralized and decentralized manufacturing models, enabling increased access to life changing therapies at reduced costs. Together, we deliver consistent, high-purity cells that set the foundation for better therapies — and real clinical success.
